BioCentury | Jul 10, 2020
Product Development

Atox looks towards 3Q20 NDA submission for necrotizing infection candidate following Phase III readout

...produce toxins including lipopolysaccharides that can induce excessive inflammation, and progress to multisystem organ failure. Atox Bio Ltd....
...December 2019 for sepsis-associated acute kidney injury due to slow patient enrollment. Sandi Wong, Assistant Editor reltecimod (AB103) Atox Bio Ltd. CD28 necrotizing...
BioCentury | Feb 16, 2019
Company News

Management tracks: Nimbus, Ascentage, Cadent, Skyhawk

...Leen Thielemans to chief development officer from head of development. Infectious disease and renal company Atox Bio Ltd....
BioCentury | Dec 8, 2017
Financial News

Atox Bio raises $30M series F

...On Dec. 4, Atox Bio Ltd. (Ness Ziona, Israel) raised $30 million in a series F round led...
...Jonathan Tobin and Adams Street's Terry Gould will join Atox's board. Atox Bio Ltd., Ness Ziona, Israel Jennie Walters AB103 reltecimod Atox Bio Ltd. CD28...
BioCentury | Dec 4, 2017
Financial News

Atox Bio raises $30M series F

...trials in 2019. Arix's Jonathan Tobin and Adams Street's Terry Gould will join Atox's board. Jennie Walters AB103 reltecimod Atox Bio...
BioCentury | Jun 9, 2017
Clinical News

Reltecimod passes futility analysis in Phase III

...the ICU and duration of hospital stay. Reltecimod is a short peptide that modulates CD28. Atox Bio...
...days in the ICU and duration of hospital stay Status: Phase III ongoing Milestone: NA Alicia Parker AB103 Atox Bio...
BioCentury | Nov 2, 2016
Distillery Therapeutics

Infectious disease; inflammation

...TARGET/MARKER/PATHWAY: CD86 (B7-2) LICENSING STATUS: Patent application filed by Yissum Research Development Company; licensed to Atox Bio...
BioCentury | Jun 20, 2016
Company News

Atox Bio, U.S. Department of Health and Human Services infectious news

...peptide that modulates CD28, is in Phase III testing to treat necrotizing soft tissue infections. Atox Bio...
BioCentury | Jan 4, 2016
Clinical News

AB103: Phase III started

...during or after surgical debridement plus the standard of care (SOC) in about 290 patients. Atox Bio...
BioCentury | Aug 18, 2014
Clinical News

AB103 regulatory update

...the U.S. for the indication. In 2H15, the company plans to start a pivotal trial. Atox Bio...
BioCentury | Jul 28, 2014
Financial News

Atox Bio completes venture financing

Atox Bio Inc. , Ness Ziona, Israel Business: Infectious, Autoimmune Date completed: 2014-07-24 Type: Venture financing Raised: Not disclosed Investors: SR One; Lundbeckfond Ventures; OrbiMed Advisors Note: Atox raised an undisclosed amount in the first of...
Items per page:
1 - 10 of 21
BioCentury | Jul 10, 2020
Product Development

Atox looks towards 3Q20 NDA submission for necrotizing infection candidate following Phase III readout

...produce toxins including lipopolysaccharides that can induce excessive inflammation, and progress to multisystem organ failure. Atox Bio Ltd....
...December 2019 for sepsis-associated acute kidney injury due to slow patient enrollment. Sandi Wong, Assistant Editor reltecimod (AB103) Atox Bio Ltd. CD28 necrotizing...
BioCentury | Feb 16, 2019
Company News

Management tracks: Nimbus, Ascentage, Cadent, Skyhawk

...Leen Thielemans to chief development officer from head of development. Infectious disease and renal company Atox Bio Ltd....
BioCentury | Dec 8, 2017
Financial News

Atox Bio raises $30M series F

...On Dec. 4, Atox Bio Ltd. (Ness Ziona, Israel) raised $30 million in a series F round led...
...Jonathan Tobin and Adams Street's Terry Gould will join Atox's board. Atox Bio Ltd., Ness Ziona, Israel Jennie Walters AB103 reltecimod Atox Bio Ltd. CD28...
BioCentury | Dec 4, 2017
Financial News

Atox Bio raises $30M series F

...trials in 2019. Arix's Jonathan Tobin and Adams Street's Terry Gould will join Atox's board. Jennie Walters AB103 reltecimod Atox Bio...
BioCentury | Jun 9, 2017
Clinical News

Reltecimod passes futility analysis in Phase III

...the ICU and duration of hospital stay. Reltecimod is a short peptide that modulates CD28. Atox Bio...
...days in the ICU and duration of hospital stay Status: Phase III ongoing Milestone: NA Alicia Parker AB103 Atox Bio...
BioCentury | Nov 2, 2016
Distillery Therapeutics

Infectious disease; inflammation

...TARGET/MARKER/PATHWAY: CD86 (B7-2) LICENSING STATUS: Patent application filed by Yissum Research Development Company; licensed to Atox Bio...
BioCentury | Jun 20, 2016
Company News

Atox Bio, U.S. Department of Health and Human Services infectious news

...peptide that modulates CD28, is in Phase III testing to treat necrotizing soft tissue infections. Atox Bio...
BioCentury | Jan 4, 2016
Clinical News

AB103: Phase III started

...during or after surgical debridement plus the standard of care (SOC) in about 290 patients. Atox Bio...
BioCentury | Aug 18, 2014
Clinical News

AB103 regulatory update

...the U.S. for the indication. In 2H15, the company plans to start a pivotal trial. Atox Bio...
BioCentury | Jul 28, 2014
Financial News

Atox Bio completes venture financing

Atox Bio Inc. , Ness Ziona, Israel Business: Infectious, Autoimmune Date completed: 2014-07-24 Type: Venture financing Raised: Not disclosed Investors: SR One; Lundbeckfond Ventures; OrbiMed Advisors Note: Atox raised an undisclosed amount in the first of...
Items per page:
1 - 10 of 21